# CR-002

Source: https://onco.cc/drugs/cr-002/  
OnCo record `cr-002` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CR-002 is an experimental antibody-drug conjugate from Crescent Biopharma, in phase 1 trials for non-small cell lung cancer, head and neck squamous cell carcinoma and advanced solid tumours.

## Summary

CR-002 is an antibody-drug conjugate (topoisomerase inhibitor payload) from Crescent Biopharma. An antibody-drug conjugate that uses a highly internalising PD-L1 antibody to carry a topoisomerase inhibitor payload into tumour cells, with a linker designed to be cleaved inside the cell. Its furthest stage is phase 1, for non-small cell lung cancer, head and neck squamous cell carcinoma and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. FDA cleared the IND; the APOLLO phase 1/2 trial (NCT07909031) is listed as recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: CR-002
- Modality: Antibody-drug conjugate (topoisomerase inhibitor payload)
- Mechanism: An antibody-drug conjugate that uses a highly internalising PD-L1 antibody to carry a topoisomerase inhibitor payload into tumour cells, with a linker designed to be cleaved inside the cell.

## Sources

- Crescent Biopharma: crescentbiopharma.com: https://www.crescentbiopharma.com/pipeline
- Crescent Biopharma: crescentbiopharma.com: https://www.crescentbiopharma.com/pipeline
- Crescent Biopharma: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07909031
- ClinicalTrials.gov: trials of CR-002: https://clinicaltrials.gov/search?intr=CR-002

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Crescent Biopharma](https://onco.cc/companies/crescent-biopharma/)
- trials: [CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07909031/)

---
JSON: https://onco.cc/api/v1/entities/cr-002.json